General Biotechnology

Drug Patent Expirations for May 11 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE 
Who are the leading pharmaceutical patent challengers? A report on Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan		Premium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan
comparison    Site
tour    Contact





Drug Patent Expirations for May 11 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
ALLEGRASanofi Aventis
Us		fexofenadine hydrochloride6,187,791May 11,
2012
ALLEGRASanofi
Aventis Us		fexofenadine hydrochloride6,399,632May 11,
2012
CHILDREN’S ALLEGRA
ALLERGY		Sanofi Aventis Usfexofenadine
hydrochloride		6,187,791May 11, 2012
CHILDREN’S ALLEGRA ALLERGYSanofi
Aventis Us		fexofenadine hydrochloride6,399,632May 11,
2012
CHILDREN’S ALLEGRA
HIVES		Sanofi Aventis Usfexofenadine hydrochloride6,187,791May 11,
2012
CHILDREN’S ALLEGRA
HIVES		Sanofi Aventis Usfexofenadine hydrochloride6,399,632May 11,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview and Plan
Comparison. Contact Us with any
questions.




The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Drug Patent Expirations for May 11 2012 Read Post »

General Biotechnology

Drug Patent Expirations for May 9 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE 

This
newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan		Premium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan
comparison    Site
tour    Contact





Drug Patent Expirations for May 9 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
CRIXIVANMerck Sharp
Dohme		indinavir sulfate5,413,999May 9,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview and Plan
Comparison. Contact Us with any
questions.




The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Drug Patent Expirations for May 9 2012 Read Post »

Biotechblog
Scroll to Top